---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-027712"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:18:53.233453+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools reports Q4 pro forma revenue $46.7M, down 9% YoY; 2025 guidance $165-175M

## Summary
- Q4 pro forma revenue $46.7M (down 9% YoY); full year $175.1M (down 9% YoY).
- Q4 net loss $34.1M improved from $55.3M loss; adjusted EBITDA loss $18.4M (34% improvement).
- Achieved $90M in operational cost synergies, exceeding original target by $10M; cash $295M, no debt.
- 2025 revenue guidance $165M-$175M, citing anticipated NIH funding pressure and no tariff impact.
- Full year consumables revenue up 18% YoY; instruments down 27%; services down 17%.

## SEC filing metadata
- accession: 0000950170-25-027712
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000095017025027712/0000950170-25-027712-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000095017025027712/lab-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-027712
- JSON: https://secwatch.observer/filing/0000950170-25-027712.json
- Plain text: https://secwatch.observer/filing/0000950170-25-027712.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.